Evidence map›Paper›PMID 31865786›Full record

ReviewHypertension (Dallas, Tex. : 1979)2020

High Blood Pressure and Cardiovascular Disease.

Flávio D Fuchs, Paul K Whelton

3 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hypertension (Dallas, Tex. : 1979), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 993 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
993citing papers in PubMed, 11 pooled it
65.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05880056 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

A Prospective, Multicenter, Open-label, Single-arm Interventional Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension

TypeinterventionalSponsorGenuine Research Center, EgyptRan2024 to 2025Enrolled406ConditionsEssential HypertensionArmsNerkardou (5 mg) & (10 mg)
NCT06988501 narecruitingnot on this mapstarted 2024, after this paper: background citation

The Effect of Goal Setting With Mobile-based Self-management Tool on Improving Diet Quality of People With High Blood Pressure: a Randomized Controlled Trial

TypeinterventionalSponsorChina National Center for Cardiovascular DiseasesRan2024 to 2025Enrolled110ConditionsBlood Pressure, HighArmsGoal setting with mobile-based self-management tool, Nutrition education
NCT07547345 narecruitingnot on this mapstarted 2026, after this paper: background citation

Live Healthy Chicago - Community Pilot

TypeinterventionalSponsorRush University Medical CenterRan2026 to 2027Enrolled200ConditionsHypertensionArmsCommunity-Based Multidisciplinary Hypertension Management Program
3 · Its place in the literature

Who cites it

993 citing papers in PubMed, 11 syntheses or guidelines pooled it, 1,829 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Association BetweenInternational journal of environmental research and public health · 2026
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

933 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Flávio D FuchsFrom the Division of Cardiology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil (F.D.F.).
Paul K WheltonDepartments of Epidemiology and Medicine, Tulane University, New Orleans, LA (P.K.W.).
Hospital de Clínicas de Porto Alegre · BR

Funding

Tulane COBRE in Cardiometabolic Diseases Clinical Research CoreP20GM109036 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI JING CHEN · 2016 to 2026
$25.3M
NIGMS NIH HHS P20 GM109036
6 · The paper itself

Abstract

Fragmented investigation has masked the overall picture for causes of cardiovascular disease (CVD). Among the risk factors for CVD, high blood pressure (BP) is associated with the strongest evidence for causation and it has a high prevalence of exposure. Biologically, normal levels of BP are considerably lower than what has typically been characterized as normal in research and clinical practice. We propose that CVD is primarily caused by a right-sided shift in the population distribution of BP. Our view that BP is the predominant risk factor for CVD is based on conceptual postulates that have been tested in observational investigations and clinical trials. Large cohort studies have demonstrated that high BP is an important risk factor for heart failure, atrial fibrillation, chronic kidney disease, heart valve diseases, aortic syndromes, and dementia, in addition to coronary heart disease and stroke. In multivariate modeling, the presumed attributable risk of high BP for stroke and coronary heart disease has increased steadily with progressive use of lower values for normal BP. Meta-analysis of BP-lowering randomized controlled trials has demonstrated a benefit which is almost identical to that predicted from BP risk relationships in cohort studies. Prevention of age-related increases in BP would, in large part, reduce the vascular consequences usually attributed to aging, and together with intensive treatment of established hypertension would eliminate a large proportion of the population burden of BP-related CVD.

Indexed as

Cardiovascular DiseasesHypertensionPreventive Health ServicesAgingCausalityHumansPublic HealthRisk Factors

Identifiers

PMID31865786
PMCPMC10243231
OpenAlexW2998223455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.